A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer

Upregulation of Notch pathway is associated with poor prognosis in breast cancer. We present the results of a phase I study of an oral selective gamma secretase (GS) inhibitor (critical to Notch signaling), RO4929097 in combination with neoadjuvant chemotherapy for operable triple negative breast ca...

Full description

Saved in:
Bibliographic Details
Published in:Invest New Drugs
Main Authors: Sardesai, Sagar, Badawi, Mohamed, Mrozek, Ewa, Morgan, Evan, Phelps, Mitch, Stephens, Julie, Wei, Lai, Kassem, Mahmoud, Ling, Yonghua, Lustberg, Maryam, Stover, Daniel, Williams, Nicole, Layman, Rachel, Reinbolt, Raquel, VanDeusen, Jeffrey, Cherian, Mathew, Grever, Michael, Carson, William, Ramaswamy, Bhuvaneswari, Wesolowski, Robert
Format: Artigo
Language:Inglês
Published: 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7955776/
https://ncbi.nlm.nih.gov/pubmed/31953695
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00895-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items